Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas
French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...
Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer
China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...
Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA
China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...
Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...
MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation
On November 22, China General Technology (Group) Holding released three official announcements through its official...
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation
Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official...
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...
First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...
Bayer’s Nubeqa Files for FDA Approval in mHSPC
German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...
MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion
The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...
China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors
China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...
Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance
US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second...
Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements
The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company...
Easton Pharmaceutical Secures NMPA Approval for Generic Jakavi and Urocit-K
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...
Innorna’s mRNA Drug IN015 Earns Orphan Drug Designation for PFIC Treatment
Shenzhen-based Innorna Co., Ltd, a leading platform company specializing in mRNA technology and LNP (lipid...